Pseudomonas aeruginosa Vaccines
Creative Biolabs is a leader in the field of vaccine development and has focused on the bacterial vaccines for years. We have experienced experts and advanced platforms that are able to provide excellent services for bacterial vaccine development services for Pseudomonas aeruginosa. We guarantee the finest results for our customers all over the world.
Pseudomonas aeruginosa vaccine is a Gram-negative bacterial vaccine that protects against Pseudomonas aeruginosa. P. aeruginosa is an opportunistic pathogen that is related to a wide variety of diseases or infections, such as the genetic disease cystic fibrosis (CF), necrotizing enterocolitis (NEC), and diffuse bronchopneumonia. P. aeruginosa is a ubiquitous organism, readily found in soil, aquatic and skin flora environments. The studies show that a number of P. aeruginosa strains have been proven to be the causes of different types of diseases, which are associated with markedly increased morbidity and mortality. In human, P. aeruginosa can infect many parts of body, including airway, urinary tract. Several vaccines for Pseudomonas aeruginosa have been developed and they have played important roles in the prevention of P. aeruginosa infections.
Fig.1 Representation of P. aeruginosa Microevolution During Infection in CF Airways. (Sousa A.M, et al., 2014)
The LPS-based Pseudomonas aeruginosa Vaccines
Pseudomonas aeruginosa is the cause of serious infections in humans, such as pneumonia, gastrointestinal infection, urinary tract infection, and skin or soft tissue infections. The study indicates that P. aeruginosa is an increased risk for individual after age 60, with a remarkably high annual incidence. Vaccines aimed at reducing infection with Pseudomonas aeruginosa have been developed for ten years. The data suggest that it is an effective and efficient way of P. aeruginosa prevention.
The most common vaccines for P. aeruginosa prevention are LPS-based. LPS O antigen can trigger highly immune reaction against P. aeruginosa infections. The LPS vaccine is developed based on the Salmonella typhimurium strain of P. aeruginosa and the efficacy has been proven in adult patients with leukemia and cystic fibrosis. However, the LPS-based vaccines also show toxicity in many studies owing to the lipid moiety of O-PS region. Currently, research has introduced LPS into liposomes to mask the toxic lipid A moieties, and the results show the toxicity of this vaccine is significantly decreased. In addition, due to the diversity of O-PS portions of P. aeruginosa LPS molecules, the broad protection against all P. aeruginosa strains has been a common issue for LPS-based vaccine development.
The Live Attenuated Pseudomonas aeruginosa vaccines
The live attenuated vaccine strategies are usually based on a recombinant protein or using a plasmid DNA encoding the antigen. However, the deletion mutants of P. aeruginosa have also been widely used in live attenuated vaccine development, such as a deletion of the aroA gene. The aroA deletion vaccine has proven to be both highly attenuated and immunogenic in animal models. This vaccine based on strain PA14 can provide effective protection against acute lethal pneumonia, suggesting a T cell immune reaction. Meanwhile, studies also indicate that live-attenuated P. aeruginosa vaccines have shown a good protective efficacy in a number of mice models, such as neutropenic pneumonia, lung infection, as well as leukemia. The live attenuated vaccine against P. aeruginosa has been proven to be useful to get an overview of the current state of vaccine development for CF patients. However, the vaccine development research has not yet managed to go beyond human clinical trials.
Our Services for Pseudomonas aeruginosa Vaccines
Our platforms have equipped a team of experienced scientists to provide the best strategy and protocols customized to P. aeruginosa vaccines development project. We provide global solutions for vaccine development, a seamless, high-quality, single-source value chain from discovery to commercialization.
- High batch-to-batch consistency
- Suitable for large-scale production of Pseudomonas aeruginosa
- High cost performance
- Easy for storage and easy to transport
- Authoritative certification reports
Creative Biolabs is a leader in the field of vaccine development and has focused on the vaccine development and qualification services for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.
Reference
- Sousa A.M, et al. (2014). “Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs-A Review.” Pathogens. 3(3), 680-703.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
